4-[(4-methylpiperazin-1-yl)methyl]-N-[2-methyl-5-[(5-thiophen-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
C28H30N6OS — CID 11691791
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[(4-methylpiperazin-1-yl)methyl]-N-[2-methyl-5-[(5-thiophen-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-[2-methyl-5-[(5-thiophen-3-ylpyrimidin-2-yl)amino]phenyl]benzamide (PubChem CID 11691791) has the molecular formula C28H30N6OS and a molecular weight of 498.66 g/mol. Its IUPAC name is 4-[(4-methylpiperazin-1-yl)methyl]-N-[2-methyl-5-[(5-thiophen-3-ylpyrimidin-2-yl)amino]phenyl]benzamide.
Molecular Properties
| Compound Name | 4-[(4-methylpiperazin-1-yl)methyl]-N-[2-methyl-5-[(5-thiophen-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
|---|---|
| PubChem CID | 11691791 |
| Molecular Formula | C28H30N6OS |
| Molecular Weight | 498.66 g/mol |
| Exact Mass | 498.22 |
| IUPAC Name | 4-[(4-methylpiperazin-1-yl)methyl]-N-[2-methyl-5-[(5-thiophen-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| SMILES | Cc1ccc(Nc2ncc(-c3ccsc3)cn2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1 |
| InChI | InChI=1S/C28H30N6OS/c1-20-3-8-25(31-28-29-16-24(17-30-28)23-9-14-36-19-23)15-26(20)32-27(35)22-6-4-21(5-7-22)18-34-12-10-33(2)11-13-34/h3-9,14-17,19H,10-13,18H2,1-2H3,(H,32,35)(H,29,30,31) |
| InChIKey | OZDGVHCTQCKTNG-UHFFFAOYSA-N |
| XLogP | 5.26 |
| TPSA | 73.39 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 498.66 |
| LogP ≤ 5 | 5.26 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 11691791 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.